Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?

Fig. 2

Bar graph showing the long-term improvement in clinical outcome of neurotrophic keratopathy after cenegermin treatment. A There was a significant improvement in corneal sensitivity from baseline to end of treatment and at follow-up (at 12, 24, 36, and 48 months). B There was a significant improvement in tear production (Schirmer test) from baseline to end of treatment and at follow-up (at 12, 24, and 36 months). C There was a significant improvement in best corrected distance visual acuity (BCDVA) from baseline to end of treatment and at follow-up (at 12, 24, and 36 months). *P < 0.05

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172